Review article: biofilm formation by Helicobacter pylori as a target for eradication of resistant infection.
Study Design
- Type d'étude
- Review
- Population
- H. pylori-infected patients
- Intervention
- Review article: biofilm formation by Helicobacter pylori as a target for eradication of resistant infection. None
- Comparateur
- None
- Critère de jugement principal
- H. pylori biofilm formation and treatment implications
- Direction de l'effet
- Neutral
- Risque de biais
- Unclear
Abstract
BACKGROUND: Helicobacter pylori is one of the most common causes of bacterial infection in humans. Resistance of this infection to conventional therapies has suggested the role of a biofilm-growing bacterium, which is recalcitrant to many antimicrobial agents. AIM: To review the current knowledge on biofilm formation by H. pylori and to discuss the implications of this behaviour in the context of human infections and their treatment. RESULTS: Scanning electron microscopy analysis of gastric biopsies of infected patients demonstrated that H. pylori forms biofilm on the gastric mucosa epithelium. Adaptation to the biofilm environment may produce many persister cells, namely dormant cells, which are highly tolerant to antimicrobials that could account for the recalcitrance of H. pylori infections in vivo. Resistant H. pylori infection has become increasingly common with triple or quadruple therapy, even in the presence of H. pylori strains susceptible to all antibiotics. The mucolytic and thiol-containing antioxidant N-acetylcysteine, associated with antibiotics, was successfully used in clinic for therapy of patients with chronic respiratory tract infections. Consistently, N-acetylcysteine treatment prior to starting antibiotic therapy allowed the disappearance of gastric biofilm in all patients in whom H. pylori was eradicated. CONCLUSION: Effective strategies targeting H. pylori biofilm infections are possible, through the use of substances degrading components of the biofilm.
En bref
Resistance of this infection to conventional therapies has suggested the role of a biofilm‐growing bacterium, which is recalcitrant to many antimicrobial agents.
Used In Evidence Reviews
Similar Papers
Digestion · 2016
Reduced Abundance of Butyrate-Producing Bacteria Species in the Fecal Microbial Community in Crohn's Disease.
Gut · 1996
Evaluating the antioxidant potential of new treatments for inflammatory bowel disease using a rat model of colitis.
Journal of nanobiotechnology · 2022
Oral administration of turmeric-derived exosome-like nanovesicles with anti-inflammatory and pro-resolving bioactions for murine colitis therapy.
Frontiers in endocrinology · 2024
The emerging role of oxidative stress in inflammatory bowel disease.
The British journal of nutrition · 2012
Omega-3 fatty acids and inflammatory bowel diseases - a systematic review.
Helicobacter · 2007